iSTAR Medical is a clinical-stage, medical technology company focused on the development of novel ophthalmic implants for patients with glaucoma, the second leading cause of adult blindness globally. iSTAR Medical has exclusive rights to the STAR® material from the University of Washington in Seattle (USA) for ophthalmic use. The porous material exhibits outstanding anti-fibrotic and anti-inflammatory properties providing the foundation for the development of MINIjectTM, designed to be a best-in-class micro-invasive glaucoma surgery (MIGS) device. MIGS is the most promising and fastest-growing therapeutic option for the treatment of glaucoma, the fast-growing MIGS market being expected to reach $2.0bn worldwide by 2028.